The proposition for Zalbin albinterferon alfa-2b from Human Genome Sciences Inc. (NASDAQ:HGSI) and Novartis AG (NYSE:NVS; SIX:NOVN) has always been that its longer half-life should allow less frequent dosing without sacrificing efficacy compared with pegylated interferons to treat HCV. But after multiple Phase II and III trials the partners have yet to find a dosing regimen with a sufficiently wide therapeutic window. The partners are now looking at a higher monthly dose